


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An (indol-3-yl)-heterocycle having the general Formula I



Formula I

wherein

A represents a 5-membered aromatic heterocyclic ring, wherein X<sub>1</sub>, X<sub>2</sub> and X<sub>3</sub> are independently selected from N, O, S and CR;

R is H or (C<sub>1-4</sub>)alkyl; or

R, when present in X<sub>2</sub> or X<sub>3</sub>, may form together with R<sub>3</sub> a 5-8 membered ring;

R<sub>1</sub> is a 5-8 membered saturated carbocyclic ring, optionally containing a heteroatom selected from O and S;

R<sub>2</sub> is H, CH<sub>3</sub> or CH<sub>2</sub>-CH<sub>3</sub>; or

R<sub>3</sub> and R<sub>4</sub> are independently H; or (C<sub>1-6</sub>)alkyl or (C<sub>3-7</sub>)cycloalkyl, the alkyl groups being optionally substituted with OH, (C<sub>1-4</sub>)alkyloxy, (C<sub>1-4</sub>)alkylthio, (C<sub>1-4</sub>)alkylsulfonyl, CN or halogen; or

R<sub>3</sub> together with R<sub>4</sub> and the N to which they are bonded form a 4-8 membered ring piperidine, pyrrolidine, morpholine or thiomorpholine, optionally containing a further heteroatom selected

~~from O and S, and~~ is optionally substituted with OH, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, (C<sub>1-4</sub>)alkyloxy-(C<sub>1-4</sub>)alkyl, or halogen; or

R<sub>3</sub> together with R<sub>5</sub> forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, (C<sub>1-4</sub>)alkyloxy-(C<sub>1-4</sub>)alkyl, or halogen; or

R<sub>5</sub> is H or (C<sub>1-4</sub>)alkyl; or

R<sub>5</sub> together with R<sub>3</sub> forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, (C<sub>1-4</sub>)alkyloxy-(C<sub>1-4</sub>)alkyl, or halogen;

R<sub>5</sub>' is H or (C<sub>1-4</sub>)alkyl;

R<sub>6</sub> represents 1-3 substituents independently selected from H, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, CN and halogen;

R<sub>7</sub> is H, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, CN or halogen; or  
or a pharmaceutically acceptable salt thereof.

2. (Previously Presented) The (indol-3-yl)-heterocycle of claim 1, wherein R<sub>2</sub> is H.
3. (Previously Presented) The (indol-3-yl)-heterocycle of claim 1, wherein R, R<sub>5</sub>, R<sub>5</sub>' and R<sub>6</sub> are H.
4. (Previously Presented) The (indol-3-yl)-heterocycle of claim 1, wherein R<sub>1</sub> is cyclohexyl or tetrahydropyranyl.
5. (Previously Presented) The (indol-3-yl)-heterocycle of claim 1 where the heterocycle A is 1,2,4-oxadiazole (X<sub>1</sub> is N, X<sub>2</sub> is O, X<sub>3</sub> is N), 1,2,4-thiadiazole (X<sub>1</sub> is N, X<sub>2</sub> is S, X<sub>3</sub> is N) or thiazole (X<sub>1</sub> is S, X<sub>2</sub> is CR, X<sub>3</sub> is N).
6. (Previously Presented) The (indol-3-yl)-heterocycle of claim 1 which is selected from:

- 7-Chloro-3-(5-{[N-ethyl-N-(2-methoxyethyl)amino]methyl}-[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1H-indole;
  - 7-Chloro-3-{5-[(pyrrolidin-1-yl)methyl]-[1,2,4]-thiadiazol-3-yl}-1-(tetrahydropyran-4-yl)methyl-1H-indole;
  - 7-Chloro-3-(5-{[N-ethyl-N-(2-hydroxyethyl)amino]methyl}-[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1H-indole;
  - 7-Chloro-3-(4-{[N-(2-hydroxyethyl)-N-isopropylamino]methyl}-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1H-indole;
  - 7-Chloro-3-(4-{[N-ethyl-N-(2-hydroxyethyl)amino]methyl}-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1H-indole;
  - 7-Chloro-3-(4-{[N-(2-methoxyethyl)-N-methylamino]methyl}-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1H-indole; and
  - 7-Chloro-3-{5-[(2,2-dimethyl-pyrrolidin-1-yl)methyl]-[1,2,4]oxadiazol-3-yl}-1-(tetrahydropyran-4-yl)methyl-1H-indole;
- or a pharmaceutically acceptable salt thereof.

7. (Cancelled)

8. (Previously Presented) A pharmaceutical composition comprising an (indol-3-yl)-heterocycle of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable auxiliaries.

9. (Cancelled)

10. (Withdrawn) A method of treatment of pain comprising: administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of claim 1.

11. (Withdrawn) The method of claim 10, wherein the pain is selected from the group consisting of peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.
12. (Previously Presented) A pharmaceutical composition comprising an (indol-3-yl)-heterocycle of claim 5 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable auxiliaries.
13. (Previously Presented) A pharmaceutical composition comprising an (indol-3-yl)-heterocycle of claim 6 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable auxiliaries.
14. (Withdrawn) A method of treatment of pain comprising: administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of claim 5.
15. (Withdrawn) A method of treatment of pain comprising: administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of claim 6.
16. (New) The compound of claim 6, wherein the compound is  
- 7-Chloro-3-(4-([N-(2-hydroxyethyl)-N-isopropylamino]methyl)-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1H-indole or a pharmaceutically acceptable salt thereof.
17. (New) A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof of claim 16 in admixture with pharmaceutically acceptable auxiliaries.